Irinotecan for pediatric solid tumors: The memorial Sloan-Kettering experience

Maura Cosetti, Leonard H. Wexler, Elizabeth Calleja, Tanya Trippett, Michael LaQuaglia, Andrew G. Huvos, William Gerald, John H. Healey, Paul A. Meyers, Richard Gorlick

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Purpose: Irinotecan is a novel antineoplastic agent that works by inhibiting the enzyme, topoisomerase 1. Although not extensively studied in children, preclinical studies and several phase 1 trials indicate activity against a variety of relapsed solid tumors when administered on a protracted schedule. This report describes an institutional experience with irinotecan for the treatment of pediatric solid tumors. Patients and Methods: Twenty-two heavily pretreated children with multiply relapsed tumors were treated with courses of irinotecan at 20 mg/m2 per day for 10 days [(every day × 5) × 2]. Results: Of the 19 patients evaluable for response, four achieved an objective response, including two complete responses and one partial response among four patients with rhabdomyosarcoma and one additional patient with an undifferentiated sarcoma with rhabdomyoblastic features, and one patient with a fibrosarcoma had stable disease. Among three patients with non-Hodgkin lymphoma, one achieved a partial response and one had stable disease. Diarrhea was the most commonly observed toxicity. Conclusion: Irinotecan appears to have promising single-agent activity, particularly against rhabdomyosarcoma, with minimal hematopoietic toxicity, making it ideal for further evaluation in patients at high risk with newly diagnosed disease, particularly in combination with other active agents with nonoverlapping toxicities.

Original languageEnglish (US)
Pages (from-to)101-105
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume24
Issue number2
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

irinotecan
Pediatrics
Neoplasms
Rhabdomyosarcoma
Fibrosarcoma
Sarcoma
Antineoplastic Agents
Non-Hodgkin's Lymphoma

Keywords

  • Irinotecan
  • Pediatric malignancy
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Cosetti, M., Wexler, L. H., Calleja, E., Trippett, T., LaQuaglia, M., Huvos, A. G., ... Gorlick, R. (2002). Irinotecan for pediatric solid tumors: The memorial Sloan-Kettering experience. Journal of Pediatric Hematology/Oncology, 24(2), 101-105. https://doi.org/10.1097/00043426-200202000-00009

Irinotecan for pediatric solid tumors : The memorial Sloan-Kettering experience. / Cosetti, Maura; Wexler, Leonard H.; Calleja, Elizabeth; Trippett, Tanya; LaQuaglia, Michael; Huvos, Andrew G.; Gerald, William; Healey, John H.; Meyers, Paul A.; Gorlick, Richard.

In: Journal of Pediatric Hematology/Oncology, Vol. 24, No. 2, 2002, p. 101-105.

Research output: Contribution to journalArticle

Cosetti, M, Wexler, LH, Calleja, E, Trippett, T, LaQuaglia, M, Huvos, AG, Gerald, W, Healey, JH, Meyers, PA & Gorlick, R 2002, 'Irinotecan for pediatric solid tumors: The memorial Sloan-Kettering experience', Journal of Pediatric Hematology/Oncology, vol. 24, no. 2, pp. 101-105. https://doi.org/10.1097/00043426-200202000-00009
Cosetti, Maura ; Wexler, Leonard H. ; Calleja, Elizabeth ; Trippett, Tanya ; LaQuaglia, Michael ; Huvos, Andrew G. ; Gerald, William ; Healey, John H. ; Meyers, Paul A. ; Gorlick, Richard. / Irinotecan for pediatric solid tumors : The memorial Sloan-Kettering experience. In: Journal of Pediatric Hematology/Oncology. 2002 ; Vol. 24, No. 2. pp. 101-105.
@article{2a9a3893d017468cb4f769a5dc589c09,
title = "Irinotecan for pediatric solid tumors: The memorial Sloan-Kettering experience",
abstract = "Purpose: Irinotecan is a novel antineoplastic agent that works by inhibiting the enzyme, topoisomerase 1. Although not extensively studied in children, preclinical studies and several phase 1 trials indicate activity against a variety of relapsed solid tumors when administered on a protracted schedule. This report describes an institutional experience with irinotecan for the treatment of pediatric solid tumors. Patients and Methods: Twenty-two heavily pretreated children with multiply relapsed tumors were treated with courses of irinotecan at 20 mg/m2 per day for 10 days [(every day × 5) × 2]. Results: Of the 19 patients evaluable for response, four achieved an objective response, including two complete responses and one partial response among four patients with rhabdomyosarcoma and one additional patient with an undifferentiated sarcoma with rhabdomyoblastic features, and one patient with a fibrosarcoma had stable disease. Among three patients with non-Hodgkin lymphoma, one achieved a partial response and one had stable disease. Diarrhea was the most commonly observed toxicity. Conclusion: Irinotecan appears to have promising single-agent activity, particularly against rhabdomyosarcoma, with minimal hematopoietic toxicity, making it ideal for further evaluation in patients at high risk with newly diagnosed disease, particularly in combination with other active agents with nonoverlapping toxicities.",
keywords = "Irinotecan, Pediatric malignancy, Rhabdomyosarcoma",
author = "Maura Cosetti and Wexler, {Leonard H.} and Elizabeth Calleja and Tanya Trippett and Michael LaQuaglia and Huvos, {Andrew G.} and William Gerald and Healey, {John H.} and Meyers, {Paul A.} and Richard Gorlick",
year = "2002",
doi = "10.1097/00043426-200202000-00009",
language = "English (US)",
volume = "24",
pages = "101--105",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Irinotecan for pediatric solid tumors

T2 - The memorial Sloan-Kettering experience

AU - Cosetti, Maura

AU - Wexler, Leonard H.

AU - Calleja, Elizabeth

AU - Trippett, Tanya

AU - LaQuaglia, Michael

AU - Huvos, Andrew G.

AU - Gerald, William

AU - Healey, John H.

AU - Meyers, Paul A.

AU - Gorlick, Richard

PY - 2002

Y1 - 2002

N2 - Purpose: Irinotecan is a novel antineoplastic agent that works by inhibiting the enzyme, topoisomerase 1. Although not extensively studied in children, preclinical studies and several phase 1 trials indicate activity against a variety of relapsed solid tumors when administered on a protracted schedule. This report describes an institutional experience with irinotecan for the treatment of pediatric solid tumors. Patients and Methods: Twenty-two heavily pretreated children with multiply relapsed tumors were treated with courses of irinotecan at 20 mg/m2 per day for 10 days [(every day × 5) × 2]. Results: Of the 19 patients evaluable for response, four achieved an objective response, including two complete responses and one partial response among four patients with rhabdomyosarcoma and one additional patient with an undifferentiated sarcoma with rhabdomyoblastic features, and one patient with a fibrosarcoma had stable disease. Among three patients with non-Hodgkin lymphoma, one achieved a partial response and one had stable disease. Diarrhea was the most commonly observed toxicity. Conclusion: Irinotecan appears to have promising single-agent activity, particularly against rhabdomyosarcoma, with minimal hematopoietic toxicity, making it ideal for further evaluation in patients at high risk with newly diagnosed disease, particularly in combination with other active agents with nonoverlapping toxicities.

AB - Purpose: Irinotecan is a novel antineoplastic agent that works by inhibiting the enzyme, topoisomerase 1. Although not extensively studied in children, preclinical studies and several phase 1 trials indicate activity against a variety of relapsed solid tumors when administered on a protracted schedule. This report describes an institutional experience with irinotecan for the treatment of pediatric solid tumors. Patients and Methods: Twenty-two heavily pretreated children with multiply relapsed tumors were treated with courses of irinotecan at 20 mg/m2 per day for 10 days [(every day × 5) × 2]. Results: Of the 19 patients evaluable for response, four achieved an objective response, including two complete responses and one partial response among four patients with rhabdomyosarcoma and one additional patient with an undifferentiated sarcoma with rhabdomyoblastic features, and one patient with a fibrosarcoma had stable disease. Among three patients with non-Hodgkin lymphoma, one achieved a partial response and one had stable disease. Diarrhea was the most commonly observed toxicity. Conclusion: Irinotecan appears to have promising single-agent activity, particularly against rhabdomyosarcoma, with minimal hematopoietic toxicity, making it ideal for further evaluation in patients at high risk with newly diagnosed disease, particularly in combination with other active agents with nonoverlapping toxicities.

KW - Irinotecan

KW - Pediatric malignancy

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=0036171172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036171172&partnerID=8YFLogxK

U2 - 10.1097/00043426-200202000-00009

DO - 10.1097/00043426-200202000-00009

M3 - Article

C2 - 11990694

AN - SCOPUS:0036171172

VL - 24

SP - 101

EP - 105

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 2

ER -